Trabectedin Plus PLD Shows Benefit in Real-Life Ovarian Cancer Setting

Leggi l'articolo originale


Trabectedin plus pegylated liposomal doxorubicin offered clinical benefit in a real-life setting of patients with previously treated platinum-sensitive recurrent ovarian cancer.

Lascia un commento